Drug Shortages: Why They Happen And How They Can Be Solved
In 2012 nearly 1/3 of the sterile manufacturing industry’s production capacity was not being utilized due to plant closings and temporary shutdowns for quality issues. The FDA attributes over half of all drug shortages to quality or manufacturing issues that force drug production facilities to either partially or permanently shut down.
WHITE PAPERS & CASE STUDIES
This white paper from BIO-G looks at how to create flexible, agile manufacturing facilities to respond to the current glut of biomanufacturing capacity and industry consolidation. Future proofing these facilities for higher titers and multiple product lines is also explored.
Modular Does Not Always Mean Flexible For Pharmaceutical Facilities
Lately, the pharmaceutical industry has become increasingly interested in flexible facilities. By Maik W. Jornitz, Chief Operating Officer, G-CON Manufacturing
Flexible Production Platforms For Biopharmaceutical Manufacturing
A paradigm shift in flexible biopharmaceutical production sites and process designs has been recognized in multiple scientific publications and conferences.
Use Of Hydrogen Peroxide Vapor Biodecontamination Technology For Facility Commissioning
Whether it is a new laboratory research facility or renovation of an existing facility, a sound commissioning process is vital to start-up success. By Arthur Papineau, BS ChE, MBA and John Klostermyer, PhD, STERIS Life Sciences
The Need For Flexible Facility Designs
Currently the need of a paradigm shift in the facility design of pharmaceutical and biopharmaceutical production sites has been stated in multiple papers and conferences (1, 2, 3).
Decontaminate A Pharmaceutical Production Facility In Less Than 24 Hours
Bioquell's Room Bio-Decontamination Service (RBDS) was the only solution for the a major multinational pharmaceutical company that required their production lines within a European manufacturing facility to be sterilized in a short period of time.